Neomycin ELISA Kit (DEIA043)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
Chicken, milk
Species Reactivity
Chicken
Intended Use
This kit can be used in quantitative and qualitative analysis of neomycin residue in chicken and milk.
Contents of Kit
1. Microtiter plate with 96 wells coated with antigen
2. Neomycin standard solutions(6×1ml/bottle)
0ppb, 0.5ppb, 1.5ppb, 4.5ppb, 13.5ppb, 40.5ppb
3. Spiking standard solution: 1ml, 10ppm
4.Antibody solution (7ml)………………………green cap
5. Enzyme conjugate (7ml) ………………………red cap
6. Substrate solution A (7ml)……………………white cap
7. Substrate solution B (7ml)………………………red cap
8.Stop solution (7ml)……………………………yellow cap
9.20×concentrated wash solution (40ml)
………………………….………………….transparent cap
10.2×concentrated extraction solution (50ml)
……………………………………………………..blue cap
Storage
Storage condition: 2-8°C.
Storage period: 12months.
Precision
Variation coefficient of the ELISA kit is less than 10%.
Detection Limit
Meat, 10ppb
Milk, 10ppb
Accuracy
Meat, 100±20%
Milk, 100±20%
Sensitivity
0.5ppb
General Description
Neomycin is an aminoglycoside antibiotic, which is broadly applied in animal disease treatment. For it has neurotoxicity and kidney toxicity, its residue in animal derived food is harmful to human; it is strictly controlled in use in EU, US and China. At present, ELISA is the common approach in supervision and control of aminoglycoside drug.
This kit is a new product for drug residual detection based on ELISA technology, which only costs 45min in each operation and can considerably minimize operation errors and work intensity.

Citations


Have you cited DEIA043 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Reconstruction of the Neopulmonary Root After Coronary Button Harvest for Arterial Switch Operation Using 2-ply Extracellular Matrix (Tyke): A Post-Implant Histology

FRONTIERS IN CARDIOVASCULAR MEDICINE

Authors: Bibevski, Steve; Ruzmetov, Mark; Ladich, Elena; Mendoza, Laura E.; Scholl, Frank G.

In children with Transposition of the Great Arteries (TGA), the pulmonary artery, and aorta are connected to the heart abnormally resulting in blue blood (deoxygenated) recirculating to the body and red blood (oxygenated) recirculating to the lungs. The arterial switch operation (ASO) is the standard of care for transposition of the great arteries (TGA), and given the low risk of early mortality and satisfactory long-term outcomes, focus is now on managing longer term complications such as neo-aortic root dilatation, and pulmonary artery stenosis. Since May 2016, we have used 2-ply extracellular matrix (ECM; Tyke) for reconstruction of the coronary button defects using a pantaloon patch. We present histology of implanted 2-ply ECM (Tyke) from a patient who went back to surgery for development of subaortic stenosis similar to 12 months after ASO.

SABR-BRIDGE:StereotacticABlativeRadiotherapyBeforeResection to AvoIdDelay for Early-Stage LunGCancer or OligomEts During the COVID-19 Pandemic

FRONTIERS IN ONCOLOGY

Authors: Kidane, Biniam; Spicer, Jonathan; Kim, Julian O.; Fiset, Pierre-Olivier; Abdulkarim, Bassam; Malthaner, Richard; Palma, David

Surgical resection is the standard-of-care approach for early-stage non-small cell lung cancer (NSCLC). Surgery is also considered an acceptable standard infit patients with oligometastatic lesions in the lungs. The COVID-19 pandemic has led to worldwide issues with access to operating room time, with patients and physicians facing uncertainty as to when surgical resection will be available, with likely delays of months. Further compounding this are concerns about increased risks of respiratory complications with lung cancer surgery during active phases of the pandemic. In this setting, many thoracic oncology teams are embracing a paradigm where stereotactic ablative radiotherapy (SABR) is used as a bridge, to provide radical-intent treatment based on a combination of immediate SABR followed by planned surgery in 3-6 months. This pragmatic approach to treatment has been named SABR-BRIDGE (Stereotactic ABlative Radiotherapy Before Resection to avoId Delay for early-stage lunG cancer or oligomEts). This term has also been applied to the pragmatic study of the outcomes of this approach. In this paper, we discuss the standards of care in treatment of early-stage (NSCLC) and pulmonary oligometastases, the impetus for the SABR-BRIDGE approach, and the controversies surrounding assessment of pathological response to neo-adjuvant radiation therapy.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket